Loading...
XLONBXP
Market cap204mUSD
Dec 20, Last price  
36.50GBP
1D
0.00%
1Q
69.77%
Jan 2017
-28.30%
IPO
48.75%
Name

Beximco Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XLON:BXP chart
P/E
531.71
P/S
62.48
EPS
10.34
Div Yield, %
9.63%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
17.25%
Revenues
44.39b
+13.05%
3,326,972,7173,702,289,1383,596,989,5834,010,143,0564,868,245,7826,490,813,7427,890,181,3219,289,115,28410,490,699,09411,206,885,67712,965,506,87315,508,776,97217,716,716,85522,816,629,79525,611,947,65529,493,573,86934,669,172,05239,266,662,23744,391,603,925
Net income
5.83b
+26.34%
489,230,534470,691,818353,013,003545,344,689624,794,4431,051,732,8251,198,424,9921,319,389,3281,404,762,7801,528,297,5731,954,284,5162,226,695,1242,536,543,9483,033,402,3333,514,687,3015,127,693,7115,123,136,7124,614,066,1475,829,529,200
CFO
0k
-100.00%
311,494,2431,079,631,622340,671,788880,778,163520,885,0171,198,514,4541,246,031,9171,857,380,0702,130,330,7582,215,980,4022,112,852,5982,633,964,9861,819,113,9232,959,916,9045,542,487,2216,023,263,9555,493,375,0576,084,786,8580
Dividend
Nov 10, 20232.340633 GBP/sh
Earnings
Jan 28, 2025

Profile

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
URL
https://www.beximcopharma.com/
IPO date
Oct 21, 2005
Employees
5,500
Domiciled in
BD
Incorporated in
BD

Valuation

Title
BDT in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062015‑122014‑12
Income
Revenues
44,391,604
13.05%
39,266,662
13.26%
34,669,172
17.55%
Cost of revenue
35,717,233
32,414,841
28,049,102
Unusual Expense (Income)
NOPBT
8,674,371
6,851,821
6,620,070
NOPBT Margin
19.54%
17.45%
19.09%
Operating Taxes
1,658,704
1,544,300
1,688,317
Tax Rate
19.12%
22.54%
25.50%
NOPAT
7,015,667
5,307,521
4,931,754
Net income
5,829,529
26.34%
4,614,066
-9.94%
5,123,137
-0.09%
Dividends
(1,585,901)
(1,567,923)
(1,623,099)
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
2,996,660
8,061,065
8,916,513
Long-term debt
3,090,471
4,071,529
Deferred revenue
Other long-term liabilities
5,304,551
3,170,764
2,785,073
Net debt
2,121,581
9,994,877
11,796,012
Cash flow
Cash from operating activities
6,084,787
5,493,375
CAPEX
(1,993,730)
(2,710,028)
(2,939,498)
Cash from investing activities
(2,406,459)
(2,617,018)
(7,680,054)
Cash from financing activities
(6,259,874)
(3,560,571)
2,615,225
FCF
6,997,208
4,459,639
(4,177,085)
Balance
Cash
1,054,106
1,135,686
1,168,674
Long term investments
(179,027)
20,973
23,357
Excess cash
Stockholders' equity
43,493,386
40,660,554
37,676,893
Invested Capital
60,204,114
60,948,242
59,692,330
ROIC
11.58%
8.80%
9.24%
ROCE
13.82%
10.79%
10.64%
EV
Common stock shares outstanding
446,112
446,235
446,112
Price
Market cap
EV
EBITDA
8,674,371
8,912,324
6,990,309
EV/EBITDA
Interest
1,159,702
1,285,698
1,001,836
Interest/NOPBT
13.37%
18.76%
15.13%